Magnetic Seizure Therapy for Parkinson's disease



Study Overview

- Phase 2 study evaluating the feasibility of using Magnetic Seizure Therapy (MST) to treat depression in Parkinson's Disease
- Studying the impact of MST on mood, cognition, suicidal ideation, motor function, quality of life measures, and electroencephalography
- Open label, single-arm study: All participants will receive MST twice per week under general anesthesia (max 16 treatments)


Things to Note:

MST Treatments will be delivered at Detwiller Pavilion (UBC Hospital)

every Tues-Thurs from 10:30am-noon

Participants will not be responsible for the cost of treatment.

A modest compensation for time and transportation expenses is offered.



Participants **must**be picked up by a
trusted relative or
friend after every
treatment



Inclusion Criteria



- 1. Between 50-100 years old
- 2. Confirmed diagnosis of Parkinson's disease
- 3. Moderate-severe depression
- 4. Stable doses of psychotropic medications
- 5. Able to receive convulsive therapy as assessed by a psychiatrist and anesthesiologist
- 6. If on antidepressants, agree to keep them constant during the entire study
- 7. Can adhere to the treatment schedule
- 8. Meet the MST safety criteria

Exclusion Criteria



- 1. Diagnosis of another major neurocognitive disorder (e.g., dementia)
- 2. Active psychosis
- 3. New psychotropic medications in the past 4 weeks
- 4. Require more than 2mg/day of lorazepam (or equivalent dose)
- 5. Currently take any anticonvulsants

Next Steps

Please fill out a referral form, adding a note to indicate interest in the "MST-PD study" and fax it to: 604-822-7922

https://ninet.med.ubc.ca/clinic/referral/

